Comparing the Efficacy and Safety of Vericiguat With Standard Medical Treatment in Heart Failure Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 500 participants.

Also called NCT07697833

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 500 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07697833
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07697833. Randomized; quadruple masking; primary purpose treatment. Start 2026-07-15 (anticipated); primary completion 2027-05-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparing the Efficacy and Safety of Vericiguat With Standard Medical Treatment in Heart Failure Patients
Acronym
VERICIGUAT
Intervention (Drug)
Vericiguat tablet
Intervention (Drug)
Placebo
Lead sponsor
National Institute of Cardiovascular Diseases, Pakistan (class: other)
Collaborator
Horizon Pharmaceuticals (class: not stated)

Record details

Record id
cardio:ct-nct07697833
Content hash
cc14605c33811dc0d1a24cea0812c0f50f8265cff992ab994e874d269d77190f